Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320762 | 0.92 | SPHK1 (0.53) | AGTR2SPHK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8325243 | 0.90 | SPHK1 (0.52) | AGTR2SPHK1ALDH1A1 | |
| SCHEMBL2864891 | 0.88 | AGTR2 (0.61) | AGTR2SIGMAR1ALDH1A1LMNAKMT2A | |
| SCHEMBL8409861 | 0.88 | AGTR2 (0.61) | AGTR2SIGMAR1ALDH1A1LMNAKMT2A | |
| SCHEMBL8343227 | 0.88 | AGTR2 (0.61) | AGTR2SIGMAR1ALDH1A1LMNAKMT2A | |
| SCHEMBL8318482 | 0.87 | SPHK1 (0.54) | SPHK1SIGMAR1KMT2A | |
| Hydrochloric Acid SCHEMBL5134049 | 0.87 | AGTR2 (0.60) | AGTR2SIGMAR1ALDH1A1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL8323987 | 0.86 | SPHK1 (0.53) | SPHK1SIGMAR1KMT2A | |
| SCHEMBL2628898 | 0.85 | AGTR2 (0.52) | AGTR2SIGMAR1ALDH1A1LMNA | |
| SCHEMBL7253957 | 0.85 | SIGMAR1 (0.49) | AGTR2SIGMAR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2127650-B1 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-8557979-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | FOB SYNTHESIS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8232268-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC., (US) | 2010-06-24 | — | — | US | disclosed |
| US-7683049-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2127650-A2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB Synthesis, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1765326-A4 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1765326-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB Synthesis, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060069081-A1 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | CHOI, WOO-BAEG, DR. | 2006-03-30 | — | — | US | disclosed |
| WO-2005123066-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2003062232-A1 | DERIVATIVES OF THIAZOLES USED FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SOCIETE DE CONSEILS DE RECHERCHE ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | MGAM, GSK3B, GSK3A | AGTR2 3288/4885SPHK1 1021/4885SIGMAR1 1228/4885 |
| US-20060069081-A1 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | MGAM, GSK3B, GSK3A | AGTR2 3288/4885SPHK1 1021/4885SIGMAR1 1228/4885 |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | MGAM, GSK3B, GSK3A | AGTR2 3288/4885SPHK1 1021/4885SIGMAR1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.